Bionik Laboratories Corp.
Bionik Laboratories Corp.
Your view on BNKL
Overview
What the company does, where it operates, and who runs it.
About Bionik Laboratories Corp.
- Industry
- Medical - Care Facilities
- Sector
- Healthcare
- CEO
- Richard Paul Russo Jr.
- Headquarters
- 80 Coolidge Hill Road, Watertown, MA, US
- Industry
- Medical - Care Facilities
- Sector
- Healthcare
- CEO
- Richard Paul Russo Jr.
- Headquarters
- 80 Coolidge Hill Road, Watertown, MA, US
Bionik Laboratories Corp., a robotics company, engages in designing, developing, and commercializing physical rehabilitation technologies, prosthetics, and assisted robotic products.
It offers InMotion Robots, which include a suite of robotic rehabilitation products; InMotion ARM, an evidence-based intelligent interactive rehabilitation technology that senses patient movements and limitations; InMotion ARM/HAND, which provides support for therapy involving reaching with grasp and release movements, and individual hand movements; and InMotion Connect platform that consists of a hardware device connected to the InMotion Robot, as well as a subscription to InMotion Connect Pulse.
Bionik Laboratories Corp. was incorporated in 2010 and is headquartered in Watertown, Massachusetts.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Bionik Laboratories Corp., and the rating behind it. BNKL last traded at $0.0001; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Bionik Laboratories Corp.. Starting points for Bionik Laboratories Corp.: EPS -$0.72, beta 9.36 — an Medical - Care Facilities name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Bionik Laboratories Corp.. Bionik Laboratories Corp. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Bionik Laboratories Corp.. Trailing twelve-month EPS for Bionik Laboratories Corp. stands at -$0.72. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Bionik Laboratories Corp.. Bionik Laboratories Corp. has reported as a listed company since 2015. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Bionik Laboratories Corp. valued side by side against its closest peers. Bionik Laboratories Corp. is measured against Medical - Care Facilities peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Bionik Laboratories Corp., and how their positions are changing. At a $1,248 market value, institutional positions materially move Bionik Laboratories Corp.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Bionik Laboratories Corp. executives and directors. Shares of Bionik Laboratories Corp. have traded between $0.0000 and $0.0001 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Bionik Laboratories Corp.. Bionik Laboratories Corp. is a $1,248 Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Bionik Laboratories Corp.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Bionik Laboratories Corp.. Coverage tracks Bionik Laboratories Corp. within Medical - Care Facilities (Healthcare). Press releases and market coverage, newest first.